A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials

被引：0
|
作者：
Stanley, I. Kitty [1 ]
Palma, Anton M. [2 ]
Viecelli, Andrea K. [1 ,3 ,4 ]
Johnson, David W. [1 ,3 ,4 ]
Hawley, Carmel M. [1 ,3 ,4 ]
Staatz, Christine E. [5 ]
Mallett, Andrew J. [4 ,6 ,7 ,8 ]
机构：
[1] Univ Queensland, Ctr Hlth Serv Res, Brisbane, Qld, Australia
[2] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[3] Princess Alexandra Hosp, Dept Kidney & Transplant Serv, Brisbane, Australia
[4] Univ Queensland, Ctr Kidney Dis Res, Brisbane, Qld, Australia
[5] Univ Queensland, Sch Pharm, Brisbane, Australia
[6] Townsville Univ Hosp, Dept Renal Med, Townsville, Australia
[7] James Cook Univ, Coll Med & Dent, Townsville, Australia
[8] Univ Queensland, Inst Mol Biosci, Brisbane, Australia
来源：
JOURNAL OF NEPHROLOGY | 2024年
关键词：
D O I：
10.1007/s40620-024-01906-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A SECONDARY ANALYSIS OF CONCURRENT USE OF METFORMIN AND TOLVAPTAN IN ADPKD TOLVAPTAN TRIALS
    Stanley, Isabelle Kitty
    Palma, Anton
    Viecelli, Andrea
    Johnson, David
    Hawley, Carmel
    Staatz, Christine
    Mallett, Andrew
    [J]. NEPHROLOGY, 2023, 28 : 81 - 81
  • [2] Tolvaptan slows progression in ADPKD [Tolvaptan mindert die Progression bei ADPKD]
    Betzen C.
    [J]. Der Nephrologe, 2013, 8 (1): : 65 - 66
  • [3] ADPKD, Tolvaptan, and Nephrolithiasis Risk
    Hoorn, Ewout J.
    Zietse, Robert
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 923 - 925
  • [4] Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
    Mizuno, Hiroki
    Sekine, Akinari
    Suwabe, Tatsuya
    Ikuma, Daisuke
    Yamanouchi, Masayuki
    Hasegawa, Eiko
    Sawa, Naoki
    Ubara, Yoshifumi
    Hoshino, Junichi
    [J]. PLOS ONE, 2022, 17 (02):
  • [5] A POST HOC ANALYSIS OF STATIN USE IN TOLVAPTAN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PIVOTAL TRIALS
    Shoaf, Susan E.
    Ouyang, John
    Sergeyeva, Olga
    Estilo, Alvin
    Li, Hui
    Leung, Deborah
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) : 734 - 735
  • [6] What is the Appropriate Dose of Tolvaptan in ADPKD?
    Dahl, Neera K.
    Torres, Vicente E.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2024, 9 (04): : 737 - 739
  • [7] IMPLEMENTING A VIRTUAL NEPHROLOGY PANEL FOR TOLVAPTAN USE IN PATIENTS WITH ADPKD
    Lin Duong
    Taneja, Nidhika
    Belani, Sharina
    Irannejad, Pardis
    Jain, Anagha
    Lieberman, Jonathan
    Tuan Nguyen
    Ramaswamy, Deepa
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 590 - 590
  • [8] Compassionate use of tolvaptan in acquired megacolon secondary to autosomal dominant polycystic kidney disease (ADPKD)
    Boyano, Iris Viejo
    Velasco, Paul Jose Hernandez
    Martinez, Eduardo Gutierrez
    [J]. NEFROLOGIA, 2024, 42 (02): : 301 - 303
  • [9] REAL-LIFE USE OF TOLVAPTAN IN ADPKD: A RETROSPECTIVE ANALYSIS OF A LARGE CANADIAN COHORT
    Calvaruso, Luca
    Yau, Kevin
    Akbari, Pedram
    Nasri, Fatemeh
    Deng, Shirley X.
    Khowaja, Saima
    He, Ning
    Haghighi, Amirreza
    Khalili, Korosh
    Pei, York
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I221 - I222
  • [10] Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort
    Luca Calvaruso
    Kevin Yau
    Pedram Akbari
    Fatemah Nasri
    Saima Khowaja
    Bill Wang
    Amirreza Haghighi
    Korosh Khalili
    York Pei
    [J]. Scientific Reports, 13 (1)
12345